Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-22-053710
Filing Date
2022-04-29
Accepted
2022-04-29 16:47:08
Documents
14
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A tm2214006d1_10ka.htm   iXBRL 10-K/A 419545
2 EXHIBIT 31.1 tm2214006d1_ex31-1.htm EX-31.1 3817
3 EXHIBIT 31.2 tm2214006d1_ex31-2.htm EX-31.2 3573
  Complete submission text file 0001104659-22-053710.txt   685186

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ontx-20211231.xsd EX-101.SCH 3033
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ontx-20211231_lab.xml EX-101.LAB 36509
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ontx-20211231_pre.xml EX-101.PRE 23998
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2214006d1_10ka_htm.xml XML 5543
Mailing Address 375 PHEASANT RUN NEWTOWN PA 18940
Business Address 375 PHEASANT RUN NEWTOWN PA 18940 267-759-3681
Onconova Therapeutics, Inc. (Filer) CIK: 0001130598 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36020 | Film No.: 22876616
SIC: 2834 Pharmaceutical Preparations